LAVA Therapeutics NV
LVTX1.740USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
45.77MMarket Cap
LossP/E TTM
More Details of LAVA Therapeutics NV Company
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LAVA Therapeutics NV Info
Ticker SymbolLVTX
Company nameLAVA Therapeutics NV
IPO dateMar 25, 2021
CEOMr. Stephen A. Hurly
Number of employees34
Security typeOrdinary Share
Fiscal year-endMar 25
AddressYalelaan 60
CityUTRECHT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code3584 CM
Phone31850163100
Websitehttps://www.lavatherapeutics.com/
Ticker SymbolLVTX
IPO dateMar 25, 2021
CEOMr. Stephen A. Hurly
Company Executives of LAVA Therapeutics NV
Name
Name/Position
Position
Shareholding
Change
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
-30000.00%
Mr. Erik J. Van Den Berg
Mr. Erik J. Van Den Berg
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Joel Jean-Mairet, Ph.D.
Mr. Joel Jean-Mairet, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Nanna L. Lueneborg, Ph.D.
Ms. Nanna L. Lueneborg, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Stefan Luzi
Mr. Stefan Luzi
Non-Executive Director
Non-Executive Director
--
--
Dr. Guido Magni, M.D., Ph.D.
Dr. Guido Magni, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
-10000.00%
Mr. Edward F. Smith
Mr. Edward F. Smith
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Benjamin Winograd, M.D., Ph.D.
Mr. Benjamin Winograd, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Paul W.H.I. Parren
Dr. Paul W.H.I. Parren
Executive Vice President Head of Research and Development
Executive Vice President Head of Research and Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
-30000.00%
Mr. Erik J. Van Den Berg
Mr. Erik J. Van Den Berg
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Joel Jean-Mairet, Ph.D.
Mr. Joel Jean-Mairet, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Ms. Nanna L. Lueneborg, Ph.D.
Ms. Nanna L. Lueneborg, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Stefan Luzi
Mr. Stefan Luzi
Non-Executive Director
Non-Executive Director
--
--
Dr. Guido Magni, M.D., Ph.D.
Dr. Guido Magni, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shay Capital LLC
9.69%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.49%
Sanofi SA
7.30%
Merck & Co Inc
4.37%
Other
63.27%
Shareholders
Shareholders
Proportion
Shay Capital LLC
9.69%
Redmile Group, LLC
7.89%
BML Capital Management LLC
7.49%
Sanofi SA
7.30%
Merck & Co Inc
4.37%
Other
63.27%
Shareholder Types
Shareholders
Proportion
Corporation
15.52%
Hedge Fund
10.52%
Investment Advisor/Hedge Fund
8.11%
Investment Advisor
1.07%
Individual Investor
0.86%
Venture Capital
0.08%
Other
63.83%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
49
7.26M
27.59%
-4.78M
2025Q3
45
7.48M
28.43%
-4.70M
2025Q2
48
18.32M
69.64%
-2.74M
2025Q1
59
22.25M
84.60%
-1.27M
2024Q4
61
18.80M
71.50%
-11.80K
2024Q3
56
15.93M
60.60%
-3.34M
2024Q2
58
16.07M
61.13%
-4.19M
2024Q1
58
16.06M
61.10%
-4.38M
2023Q4
51
18.10M
68.85%
+283.15K
2023Q3
52
18.00M
68.48%
-418.56K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shay Capital LLC
2.60M
9.87%
+2.60M
--
Sep 19, 2025
Redmile Group, LLC
2.07M
7.89%
--
--
Jun 30, 2025
BML Capital Management LLC
1.97M
7.49%
+10.00K
+0.51%
Jun 30, 2025
Sanofi SA
1.92M
7.3%
--
--
Jun 30, 2025
Merck & Co Inc
1.15M
4.37%
--
--
Jun 30, 2025
Cooperatieve Gilde Healthcare IV UA
5.42M
20.61%
--
--
Sep 02, 2025
GTS Securities LLC
200.00K
0.76%
+200.00K
--
Sep 30, 2025
Rangeley Capital LLC
27.07K
0.1%
+27.07K
--
Jun 30, 2025
Hurly (Stephen A.)
151.80K
0.58%
+146.80K
+2935.98%
Sep 02, 2025
PNC Investments LLC
65.00K
0.25%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AltShares Event-Driven ETF
0%
AltShares Event-Driven ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
